

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

April 01, 2015

LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Salix Pharmaceuticals, Ltd. Salix Pharmaceuticals is a specialty pharmaceutical company that offers innovative gastroenterology treatments such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), APRISO® (mesalamine), UCERIS® (budesonide) extended release tablets and RELISTOR® (methylnaltrexone bromide).

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

www.valeant.com

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Media:

Renee E. Soto / Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com
/ mgavigan@sardverb.com

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-completes-acquisition-of-salix-pharmaceuticals-300059279.html>

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

ir@bauschhealth.com



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

877-281-6642

514-856-3855 (Canada)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com ©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

